Forte BioSciences Inc(FBRX)

POST26.300.000.00%19:56 EST

26.30+2.84+12.11%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- Institutional investors may adopt severe steps after Forte Biosciences, Inc.'s (NASDAQ:FBRX) latest 15% drop adds to a year losses
  Simply Wall St. · 01-03
  Institutional investors may adopt severe steps after Forte Biosciences, Inc.'s (NASDAQ:FBRX) latest 15% drop adds to a year losses
- Forte Biosciences CFO Antony A. Riley Acquires Common Shares
  Reuters · 01-03
  Forte Biosciences CFO Antony A. Riley Acquires Common Shares
- Forte Biosciences Grants 75,000 Stock Options to New Employee as Inducement Award
  Reuters · 2025-12-23
  Forte Biosciences Grants 75,000 Stock Options to New Employee as Inducement Award
- Forte Biosciences Initiated at Outperform by Evercore ISI Group
  Dow Jones · 2025-11-25
  Forte Biosciences Initiated at Outperform by Evercore ISI Group
- Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
  THOMSON REUTERS · 2025-11-25
  Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
- Forte Biosciences Is Maintained at Buy by Chardan Capital
  Dow Jones · 2025-11-17
  Forte Biosciences Is Maintained at Buy by Chardan Capital
- Analysts Offer Insights on Healthcare Companies: RenovoRx (RNXT) and Forte Biosciences (FBRX)
  TIPRANKS · 2025-11-15
  Analysts Offer Insights on Healthcare Companies: RenovoRx (RNXT) and Forte Biosciences (FBRX)
- Forte Biosciences posts Q3 net loss of $17.7 million
  Reuters · 2025-11-14
  Forte Biosciences posts Q3 net loss of $17.7 million
- Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update
  THOMSON REUTERS · 2025-11-14
  Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update
- Forte Biosciences Q3 Basic EPS USD -0.99
  THOMSON REUTERS · 2025-11-14
  Forte Biosciences Q3 Basic EPS USD -0.99
- Forte Biosciences to Present at Guggenheim Healthcare Innovation Conference
  Reuters · 2025-11-04
  Forte Biosciences to Present at Guggenheim Healthcare Innovation Conference
- BRIEF-Forte Biosciences Reports Inducement Grants Under Nasdaq Listing Rules
  Reuters · 2025-10-04
  BRIEF-Forte Biosciences Reports Inducement Grants Under Nasdaq Listing Rules
- Forte Biosciences Announces Equity Inducement Awards for New Employees Under 2020 Incentive Plan
  Reuters · 2025-10-04
  Forte Biosciences Announces Equity Inducement Awards for New Employees Under 2020 Incentive Plan
- Forte Biosciences Announces Promising Results from FB102 Celiac Disease Phase 1b Trial at Tampere Symposium
  Reuters · 2025-09-15
  Forte Biosciences Announces Promising Results from FB102 Celiac Disease Phase 1b Trial at Tampere Symposium
- Forte Biosciences Initiated at Buy by Guggenheim
  Dow Jones · 2025-08-18
  Forte Biosciences Initiated at Buy by Guggenheim
- Guggenheim Initiates Coverage on Forte Biosciences With Buy Rating, $75 Price Target
  MT Newswires Live · 2025-08-18
  Guggenheim Initiates Coverage on Forte Biosciences With Buy Rating, $75 Price Target
- Forte Biosciences Is Maintained at Buy by Chardan Capital
  Dow Jones · 2025-08-15
  Forte Biosciences Is Maintained at Buy by Chardan Capital
- Forte Biosciences Q2 EPS $(0.96) Beats $(1.11) Estimate
  Benzinga · 2025-08-15
  Forte Biosciences Q2 EPS $(0.96) Beats $(1.11) Estimate
- Forte Biosciences Inc. Reports Q2 2025 Net Loss of $11.25M, EPS at $(0.96), Continues Downward Trend from 2024
  Reuters · 2025-08-15
  Forte Biosciences Inc. Reports Q2 2025 Net Loss of $11.25M, EPS at $(0.96), Continues Downward Trend from 2024
- Forte Biosciences, Inc. Announces Results and Provides Update
  THOMSON REUTERS · 2025-08-15
  Forte Biosciences, Inc. Announces Results and Provides Update
Company Profile
Company Name
Forte BioSciences Inc
Market
NASDAQ
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.fortebiorx.com
Zip Code
- -
Phone
- -
Fax
- -
Introduction
Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
- 2025-11-14
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2025-11-14
  Quarterly Report
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 2025-09-30
  Employee Stock Ownership
  Form S-8 - Securities to be offered to employees in employee benefit plans
  Form S-8 - Securities to be offered to employees in employee benefit plans
- 2025-08-14
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2025-08-14
  Quarterly Report
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 2025-06-25
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2025-06-23
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2025-05-30
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2025-05-15
  Quarterly Report
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 2025-05-15
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2025-04-18
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2025-04-04
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2025-04-02
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 2025-03-28
  Annual Report
  Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
  Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
- 2025-02-07
  Employee Stock Ownership
  Form S-8 - Securities to be offered to employees in employee benefit plans
  Form S-8 - Securities to be offered to employees in employee benefit plans

1D
5D
Day
Week
Month

Loading ...

High

27.50

Open

23.61

Volume%

1.01

Low

23.59

23.46

T/O Rate

1.68%

To The Moon

Forte BioSciences Inc(FBRX)

Company Profile

Most Discussed